2022
DOI: 10.3390/medicina58091167
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study

Abstract: Background and Objectives: Individuals with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular disease. Arterial stiffness is an independent prognostic marker for cardiovascular disease development. We aimed at determining the effect of two different sodium-glucose co-transporter-2 (SGLT-2) inhibitors on ambulatory arterial stiffness in individuals with T2DM. Materials and Methods: In this single-center, single-arm, prospective study performed from January 2020 to August 2021, we planned … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 43 publications
0
1
0
Order By: Relevance
“…Previous observations in mice models of advanced macrovascular disease have claimed that treatment with the GLP-1R agonist liraglutide conferred attenuation of atherosclerosis and plaque stabilization as well as reduced vascular inflammation and oxidative stress [ 33 , 34 , 35 ]. Contemporary investigation supports the potential for liraglutide and empagliflozin to attenuate cardiac fibrosis in multiple pathological settings identified in both diabetic and nondiabetic states and scrutinize the molecular mechanisms associated with these effects [ 36 , 37 ].…”
Section: Discussionmentioning
confidence: 99%
“…Previous observations in mice models of advanced macrovascular disease have claimed that treatment with the GLP-1R agonist liraglutide conferred attenuation of atherosclerosis and plaque stabilization as well as reduced vascular inflammation and oxidative stress [ 33 , 34 , 35 ]. Contemporary investigation supports the potential for liraglutide and empagliflozin to attenuate cardiac fibrosis in multiple pathological settings identified in both diabetic and nondiabetic states and scrutinize the molecular mechanisms associated with these effects [ 36 , 37 ].…”
Section: Discussionmentioning
confidence: 99%